In recognition of his major contributions to understanding the biochemistry, molecular and cell biology of diabetic complications, Dr. Brownlee has received several honours in addition to the Claude Bernard Medal, including the American Diabetes Association's Outstanding Scientific Achievement Award.
Dr. Brownlee is an elected member of the 
Minkowski Prize -38th Minkowski Lecturer
Dr. Michael W. Stumvoll, University of Tübingen Medical Clinic, Tübingen, Germany
As a fellow in the laboratory of John Gerich (La Jolla, CA, and Rochester, NY) from 1993 -1995, Dr. Stumvoll worked on the mechanism of action of metformin. He was able to show that metformin inhibited excessive endogenous glucose production (in particular lactate conversion to glucose) in patients with Type 2 diabetes.
Dr. Stumvoll's other focus during his fellowship was the quantification of glucose production in the human kidney. He demonstrated that the kidneys contribute approximately 20% to glucose production in the fasting state, a number previously thought be close to zero.
Back in Germany in Hans Häring's laboratory in Tübingen, Germany, he developed a series of methods to in vivo characterise carriers of genetic variants relevant in the pathogenesis of Type 2 diabetes. Among these were: -isotope dilution technique coupled to a stepwise hyper-insulinemic clamp to measure insulin antilipolysis in vivo. -novel hyperglycaemic clamp technique to assess the beta cell response to a variety of secretory stimuli. -microdialysis technique (adipose tissue, muscle) -intramyocellular lipids by magnetic resonance spectroscopy.
Effects of common polymorphisms in candidate genes for Type 2 diabetes on these genotypes were studied. A further focus of his clinical experimental work was the mechanism underlying the clinical problem of hypoglycaemia unawareness (secondary to intensified insulin therapy in Type 1 diabetes). He studied the role of beta adrenergic sensitivity in the pathogenesis of hypoglycaemia unawareness. In addition to reduced catecholamine response, his group identified a major role of beta adrenergic sensitivity in loss of autonomic warning symptoms during hypoglycaemia in patients with Type 1 diabetes. More importantly, they discovered that prevention of hypoglycaemia seems to primarily improve beta-adrenergic sensitivity.
Michael Professor Boulton has published more than 250 articles, numerous reviews and book chapters and is coeditor of "The Foot in Diabetes" which is now in its 3 rd edition.
Report on Research Work
Professor Boulton's research has focussed upon the pathogenesis and management of diabetic neuropathy in foot ulceration. His early observations included, together with Professor John Ward, finding that arteriovenous shunting was commonly present in the neuropathic diabetic foot. Subsequent to this he has demonstrated the importance of abnormal pressures and loads under the diabetic foot during standing and walking, and more recently prescribed the use of ultrasound of the plantar aspect of the neuropathic foot in the determination of risk of foot ulceration. His group was the first to confirm in a prospective study that peripheral nerve dysfunction is the major contributory factor to foot ulceration in diabetic patients. In collaboration with the University of Seattle, he also described causal pathways to foot ulceration. In the area of diabetic neuropathy his group was the first to describe the potential importance of ACE inhibition in the pathogenesis of neuropathy and working with Dr. Rayaz Malik, they more recently described the potential of corneal confocal microscopy as a non-invasive way of assessing peripheral nerve function in diabetes. Lately in the area of diabetic foot ulceration, Professor Boulton has emphasised the need for appropriate control of confounding factors in studies of new treatments for neuropathic foot ulceration.
EASD/GlaxoSmithKline Burden of Diabetes Research Fellowship
Dr. Marit Eika Jørgensen, Steno Diabetes Centre, Gentofte, Denmark
Inuit Health in Transition
Since 1950 the Inuit population of the arctic region in Greenland, Canada and Alaska has undergone rapid sociocultural changes, such as urbanisation, declining dependence on subsistence hunting and fishing, and dietary changes from a sea mammal-and fish-based diet to a diet influenced by typical western dietary habits.
The Inuit population have been shown to have a low risk of developing diabetes and ischaemic heart disease. Recent studies from Alaska and Siberia suggest, that the prevalence of diabetes and CVD may be R 58 increasing as a consequence of westernisation of lifestyle. Our study of 1200 Inuit persons in Greenland and Denmark demonstrated age specific prevalence of diabetes as high or higher than what we find among the Caucasoid Danish population. This questions the hypothesis that the traditional arctic diet including high intake of fish and sea mammals protects against development of diabetes and cardiovascular disease.
More knowledge is needed about the determinants of the diseases among the Inuit and about the protective effects of the traditional lifestyle. It is therefore proposed to carry out an epidemiological study among the Inuit and Yupik of Alaska, Canada and Greenland.
A baseline survey will be carried out among people aged 35 and above with Inuit/Yupik ancestry from across the Alaskan, Canadian and Greenlandic North. It is the aim to recruit 10,000 participants. The study will focus on cardiovascular disease and diabetes.
The baseline study will give a description of the disease pattern across the Arctic and a cross-sectional description of the associations between environment, living conditions, lifestyle, risk factors and existing disease. After approximately ten years, a follow-up of the participants will take place including a registerbased follow-up and a repeated survey. In a broader context, the project will contribute to a better understanding of the health effects of the transition from a traditional lifestyle to a modern, industrialised life, which takes place in most present day developing countries. 
Brief curriculum vitae

Brief report on research work
Since 1997, I have mainly been studying the deleterious effects of chronic hyperglycaemia on the β-cell phenotype.
1. Effects of hyperglycaemia on rat β-cell gene expression We have shown that, in rats submitted to a 90% pancreatectomy, chronic hyperglycaemia triggers β-cell hypertrophy and a loss of β-cell differentiation that is characterised by reduced expression of genes involved in glucose stimulation of insulin secretion (GSIS) and of transcription factors that regulate their expression [1] . Interestingly, chronic hyperglycaemia also increases the expression of several genes repressed in normal β-cells, among which the transcription factor c-Myc and several antioxydant enzymes like heme oxygenase 1 (HO1) [1, 2] . Whereas c-Myc may contribute to β-cell apoptosis, loss of differentiation and hypertrophy, HO1 may protect β-cells from oxidative stress. We, therefore, studied the effect of glucose on β-cell cmyc and HO1 expression in vitro, and observed that the expression of both genes is minimal after culture in the presence of 10 mmol.l -1 glucose (G10) and strongly increased in either lower (G2-G5) or higher (G20-G30) glucose concentrations [3, 4] . We also found that the stimulation of islet cMyc and HO1 expression by G30 is Ca 2+ and cyclic AMP dependent and, for HO1 at least, seems to result from an increase in oxidative stress [4] . We are currently investigating the relationship between these changes in β-cell gene expression and other alterations of the β-cell phenotype.
Effects of hyperglycaemia on rat β β-cell function
It has been previously reported that β-cells chronically exposed to supraphysiological glucose concentrations are either insensitive or, in contrast, more sensitive to subsequent acute glucose stimulation. We have reinvestigated that question and observed that, after 5 days of diet-induced hyperglycaemia in the gerbil Psammomys obesus, the lack of GSIS between G5 and G10 results from the combination of two phenomena: a decrease in the maximal rate of insulin secretion likely due to β-cell degranulation, and an increase in glucose sensitivity that leads to an already elevated Deletion or mutation of the melanocortin-4-receptor (MC4R) in mice or humans leads to obesity with hyperphagia and hyperinsulinemia. MC4R mRNA is expressed in several brain sites, but it is unclear which populations of MC4R neurons are required to mediate melanocortin's effects on energy and glucose homeostasis. Our aim is to identify key neuronal sites mediating the 'anti-obesity and anti-diabetes' actions of MC4Rs.
We have generated mice, in which a lox-modified, null MC4R allele can be reactivated by Cre-recombinase. Mice homozygous for the null MC4R allele display an obesity phenotype identical to previously described MC4R knock-out mice. Reactivation of the MC4R allele in the oocyte, using ZP3-Cre mice, rescued loxmodified, null MC4R mice from their obesity.
Several areas of MC4R expression in the brain will be reactivated using mice with Cre-recombinase expression targeted to specific neuronal groups or by stereotaxic AAV-Cre-injections. Two sites of dense MC4R expression are autonomic preganglionic neurons and the hypothalamic paraventricular nucleus. Here MC4R expressing neurons co-localise with either choline-acetyl-transferase (ChAT) or NPY-Y1-receptors, respectively. We will generate transgenic mice expressing Cre-recombinase under ChAT or NPY-Y1 promoter control on the lox-modified, null MC4R background and analyse physiological phenotypes of mice, expressing MC4Rs in either autonomic preganglionic or hypothalamic PVN neurons or a combination of the two. Stereotaxic injections of AAV-Cre in lox-modified, null MC4R mice will furthermore localise important MC4R regions.
This novel technique of re-expressing a central nervous system receptor region specifically allows us to determine contributions of specific MC4R expressing neuronal groups to the regulation of energy and glucose homeostasis. Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Headquartered in Denmark, Novo Nordisk has companies and information offices in more than 60 countries.
Plan and Research Focus
The EFSD / Novo Nordisk Programme in diabetes research will accept applications within any area of basic or clinical diabetes research. Those focusing on psycho-social aspects of diabetes management and on prevention will also be most welcome. All applications will be considered on an equal basis and judged on their intrinsic scientific merit,.
Funding
Up to Euro 2.1 million will be made available over 3 years for research in the framework of the Programme and performed in Europe and its associated countries. The awards will be distributed as follows:
2004 -7 grants, each of Euro 100,000 2005 -7 grants, "up to" Euro 100,000 2006 -7 grants, "up to" Euro 100,000
Mechanisms of Support and Review
Research will be supported through the award of fixed grants, each of Euro 100,000. The duration of each award may be one year or longer, depending upon the needs of the project and as justified in the application, so long as the total budget does not exceed the fixed sum of Euro 100,000. Applications for an EFSD / Novo Nordisk Research Programme Award are invited from single notfor-profit institutions or groups of affiliated institutions from Europe and associated countries. Applications will be subject to a scientific review by a specialised and independent ad hoc committee. Funding will require approval by a joint EFSD and Novo Nordisk Board convened for this purpose. It is anticipated that applications for the grant year 2004 will be received by 1 December 2003 and approved for funding after review by March 2004.
Research Grant Applications
Applications for research grants may be subjected to pre-review (or triage) procedures. In this event, any application rejected at pre-review will not be subject to a complete scientific review.
The deadlines for receipt of research grant applications for funding in 2004 is 1 December 2003.
For the purpose of this programme, the budget of the research grants is limited to Euro 100,000 per annum. All budgets are to be prepared in Euro. For countries in which the Euro is not yet the common currency, the exchange rate (between the Euro and the local currency in the country where the work is to be performed) used for calculating the Euro budget must be mentioned under "Budget Justification". EFSD and Novo Nordisk reserve the right to increase or decrease approved funding in Euro amounts to compensate for any significant change in the exchange rate.
Application forms are available at: foundation@easd.org All applications must be prepared on the official forms and completed in strict accordance with the detailed instructions to be found on these forms. In particular, applicants are reminded that any pages in addition to the maximum of 10 allowed for the scientific section of the application will be deleted prior to review. Similarly, no applications using a font or linespacing smaller than defined in the instructions will be considered for review. Additional material (in the form of an appendix, attachment, reprints, etc.) is not acceptable and will not be sent to reviewers. 
Review Considerations
Completed applications will be evaluated in accordance with the criteria stated below for scientific / technical merit by an appropriate scientific committee convened by EFSD.
Review criteria are as follows:
• Significance: Does the study address an important problem? If the aims of the application are achieved, how will scientific knowledge be advanced? What will be the effect of the proposed studies on the concepts or methods that drive this field? • Approach: Are the conceptual framework, design, methods and analyses adequately developed, well 
Reporting Requirements
All Investigators funded by this Programme are required to submit a scientific report at the end of the funding period. Investigators must provide EFSD with early notice of papers accepted for publication and must acknowledge the support of the Programme in such papers by use of the phrase: "This work was made possible by an EFSD / Novo Nordisk Research Grant".
Competitive Renewal
Applications for renewal of a Research Programme Award will be accepted on a competitive basis, with the same review process as described in this announcement. Such applications will thus be considered in the same fashion as all other new applications received for review and without any special priority. Dr. Tim Frayling PhD, Peninsula Medical School, Exeter, UK Dr Tim Frayling was born in the UK in 1972. He graduated from York University, UK with a 2.1 in biological sciences. He then trained to be a clinical scientist in molecular genetics in the diagnostic genetics laboratory in Oxford. With this excellent grounding he joined Professor Andrew Hattersley and Dr Sian Ellard who were establishing a research team in Exeter working on the genetics of maturity-onset diabetes of the young (MODY) and Type 2 diabetes. The success of his research work leading to 5 peer reviewed publications meant he was awarded his PhD thesis on "The genetics of the beta-cell" after only 2 years of study. On completion of his thesis he was awarded a 5-year NHS career development award for work on the molecular genetics of Type 2 diabetes and birth weight. In this post he has established himself as a leading UK scientist in the genetics of Type 2 diabetes and has trained in epidemiology, statistics, bioinformatics and human physiology as well as state of the art genetic techniques. He has given national and international invited lectures, published 40 peer reviewed articles and 4 chapters/reviews, raised over £600,000 in grants and is supervising 3 PhD students.
Monogenic diabetes
Dr Frayling began his work primarily studying the role of the rare monogenic form of diabetes, Maturity onset diabetes of the young. His work established that mutations in the HNF1alpha gene are the commonest cause of MODY in the UK and that there is no obvious genotype-phenotype relationship. Work continued on MODY, with the identification of ~15% of MODY families that did not have a mutation in any of the known genes. These MODYX families were recently R 63 subjected to a genome wide screen led by Dr Frayling and collaborators from Sweden and France. The results from 26 European MODYX families established that there is no one further locus containing a MODY gene and that further genetic heterogeneity exists. Further work is continuing to study the best candidate genes to try and identify additional MODY genes.
Type 2 diabetes
Finding genes for Type 2 diabetes, where multiple genes and environmental factors are involved, has proven a challenging task. However, recent findings, of which some of Dr Frayling's work has been part, provide considerable cause for optimism and suggest that, despite a lot of hype about the power of genetics, geneticists can make a real impact on improving our understanding of Type 2 diabetes. For example, together with collaborators from the DiabetesUK Warren 2 consortium, we have shown conclusively that the K23 allele in the beta-cell potassium channel gene, Kir6.2, predisposes to Type 2 diabetes. Similar work using large case-control studies and a meta-analysis has provided strong evidence that SNP44 in the Calpain 10 gene is associated with Type 2 diabetes. There had been considerable controversy as to the role of Calpain 10, but our work goes some way to confirming that it has a role outside of the Mexican American population in which it was first identified. One of the most exciting findings resulting from Dr Frayling's work comes from the study of common variation in the Glucokinase (GCK) gene. Using four large normoglycaemic cohorts, we have shown that a G/A variant at position -30 in the islet cell promoter, present in 30% of people, raises fasting blood glucose levels. We are now spearheading efforts to establish the role of this variant in Type 2 diabetes risk and fetal growth. Initial results indicate that the variant alters birthweight in a parent of origin specific way. The presence of the minor allele in the mother raises birth weight but if the offspring inherits the minor allele from their father only, birthweight is reduced.
Together with other recent findings, Dr Frayling's work has provided a number of lessons about finding Type 2 diabetes genes. These include the probability that any single gene variant is likely to have a modest effect on disease risk and, therefore, large numbers of subjects are needed to identify risk alleles. This doesn't lessen the importance of finding these genes: alleles with small predisposing effects may be very common in the population and provide important knowledge about disease mechanisms. A further important lesson emerging from Dr Frayling's work is that younger onset patients appear to be more powerful for identifying genes by linkage. Together with the Warren 2 consortium, we have shown that patients diagnosed younger provide a disproportionate amount of evidence for linkage in a genome wide scan. In particular, young onset subjects contribute most to loci on chromosomes 1q, 8q and 10q. An additional lesson emerging is that 'monogenic' genes are excellent candidates for a role in Type 2 diabetes. Dr Frayling's work has provided strong evidence that common variation in IPF-1, Kir6.2 and Glucokinase plays a role in Type 2 diabetes susceptibility. This follows on from work of groups in Malmö and Boston which established the role of the PPARG, Pro12Ala variant in Type 2 diabetes. Each of these genes has an example where rare, severe mutations cause a Mendelian form of diabetes or related condition. Further work is continuing to investigate the role of common variation in the HNF-1alpha gene, which falls in a region of chromosome 12 linked to Type 2 diabetes.
Work on the EASD Albert Renold fellowship
Dr Frayling plans to take some of these lessons and resources to one of the leading centres for genetics and genomics, the Centre National de Genotypage, Evry, Paris, run by Prof. Mark Lathrop. There the plan is to use state of the art technology and expertise to attempt to dissect loci mapped by the Warren 2 genome wide scan and identify further loci. In addition to this genetic approach, Dr Frayling will also use the opportunity to improve his knowledge of genomic based approaches to identifying important disease pathways. Dr Frayling would like to thank the EASD for providing this unique opportunity to expand his skills and further his career in diabetes research. She has been involved in research in diabetic nephropathy and macroangiopathy, with experience in both clinical and basic science research for over fourteen years. After her graduation, she trained in the Institute of Internal Medicine of Turin (Prof P. Cavallo-Perin and Prof G. Pagano), where she was involved in clinical research in diabetes. In her work, she demonstrated alterations in albumin excretion rate in non-diabetic first-degree relatives of patients with microalbuminuria, providing evidence of a familial susceptibility to kidney disease in Type 2 diabetes mellitus. Furthermore, she has highlighted in both Type 1 and Type 2 microalbuminuric diabetic patients coagulation and lipid abnormalities that may contribute to their greater risk of cardiovascular events.
From 1994 to 2001, she worked in London in the Unit for Metabolic Medicine at Guy's Hospital, King's College London, UK (Prof. GC Viberti) firstly as Research Associate, then as R.D. Lawrence Fellow and finally as Clinical Lecturer. During her time in London, she gained experience in molecular and cell biology techniques and she set up within the unit an in vitro system to simulate the haemodynamic insult in vitro by exposing cultured cells to mechanical stretch. Her research activity focused on basic science aspects of diabetic nephropathy, and, specifically, she studied the mechanisms by which the haemodynamic insult of glomerular capillary hypertension translates into increased glomerular permeability and matrix deposition. In her work, she has demonstrated that stretch induces in mesangial cells overproduction of matrix components, cytokines (VEGF, TGF-β1, MCP-1) and cytokine receptors (AT1, TGF-β, VEGF, GLUT-1) via activation of specific intracellular signalling pathways (PKC, p60src, P38-MAPK, hexosamine biosynthetic pathway). This work has provided a better understanding of the mechanisms whereby the haemodynamic insult of glomerular capillary hypertension enhances the deleterious effects of hyperglycaemia. Back in Turin, she is currently a researcher in the Department of Internal Medicine, University of Turin, Italy, where she is working on the effect of the metabolic and haemodynamic insults on human glomerular epithelial cells. Dr Gruden's work has yielded more than 30 original publications in diabetes, nephrology and basic science. She has been invited to author several chapters in books, editorials and reviews, including the chapters on the pathogenesis of diabetic nephropathy in the 14th Edition of the "Joslin Textbook of Diabetes Mellitus", the 3rd edition of the "Textbook of Diabetes" edited by Prof J. Pickup and the 3 rd edition of the "Diabetes Mellitus: A Fundamental Clinical Text" by D. LeRoith. She was the recipient of the R.D. Lawrence Fellowship of the Diabetes-UK (1998) and the Internal Medicine Society Prize (1995) . She has presented in over 40 national and international conferences and has been a reviewer for several scientific journals.
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Announcements
The Third Annual Diabetes Technology Meeting San Francisco, USA, 6-8 November, 2003 This is an opportunity to meet and interact with the world's leaders in glucose and lactate monitoring, closed-loop insulin delivery, new insulin analogues and diabetes databases.
More information, the complete meeting agenda and on-line registration are available on the meeting website: http://www.diabetestechnology.org Meeting topics will include:
• 
